Nivolumab and Relatlimab in Patients With Advanced Melanoma Progressing on Anti–PD-1/PD-L1 Therapy
Source: Asco Post, February 2023
As reported in the Journal of Clinical Oncology by Paolo Antonio Ascierto, MD, and colleagues, the phase I/IIa RELATIVITY-020 trial part D has shown evidence of activity of the combination of nivolumab and relatlimab in patients with advanced melanoma progressing on anti–PD-1/PD-L1 therapy.
Study Details
The international trial consisted of two parts including patients with disease progression during or within 3 months of one (part D1) or one or more (part D2) anti–PD-1/PD-L1–containing regimens. In part D1 (n = 354), 189 patients received nivolumab/relatlimab at 240/80 mg once every 2 weeks, and 165 received the combination at 480/160 mg once every 4 weeks. In part D2, 164 patients received the regimen at 480/160 mg once every 4 weeks. Responses and progression-free survival were assessed by blinded independent central review.
Key Findings
Among 351 patients evaluable for response in part D1, objective response was observed in 42 patients (12.0%, 95% confidence interval [CI] = 8.8%–15.8%), with complete response in 15 (4.3%). Stable disease was observed in an additional 100 patients (28.5%) and the disease control rate was 40.5%. Median duration of response was not reached (95% CI = 12.9 months to not reached).